



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 39/00, C12N 15/00 A61K 39/12	A1	(11) International Publication Number: WO 92/11027 (43) International Publication Date: 9 July 1992 (09.07.92)
(21) International Application Number: PCT/EP91/02478 (22) International Filing Date: 20 December 1991 (20.12.91) (30) Priority data: P 40 41 045.5 20 December 1990 (20.12.90) DE (71) Applicant (for all designated States except US): MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. [DE/DE]; Bunsenstrasse 10, D-3400 Göttingen (DE). (72) Inventors; and (75) Inventors/Applicants (for US only) : MEYER, Thomas [DE/DE]; Spemannstr. 30, D-7400 Tübingen (DE). POHLNER, Johannes [DE/DE]; Gartenstr. 44, D-7400 Tübingen (DE). REUSS, Frank, U. [DE/DE]; Danziger Platz 5d, D-8755 Alzenau (DE). YAN, Zhengxin [CN/DE]; Fichtenweg 28, D-7400 Tübingen (DE).		(74) Agent: VOSSIUS & PARTNER; Siebertstrasse 4, P.O. Box 86 07 67, D-8000 Munich 86 (DE). (81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), MC (European patent), NL (European patent), SE (European patent), US. Published <i>With international search report.</i>
(54) Title: TWO-PHASE SYSTEM FOR THE PRODUCTION AND PRESENTATION OF FOREIGN ANTIGENS IN HYBRID LIVE VACCINES (57) Abstract <p>The present invention relates to a genetic engineering process for the optimal production and exposure to the immune system of additional antigen coded for by a live vaccine. The genetic engineering process is based on the use of spontaneous DNA reorganisation in the recombinant live vaccine, such that the recombinant live vaccine spontaneously divides into two subpopulations (A and B), whereby subpopulation A is capable of infecting and acts immunogenically per se as a minimum characteristic and subpopulation B as a minimum characteristic is regenerated by subpopulation A, produces additional antigen and acts immunogenically with respect to said additional antigen. The formation of two subpopulations of the live vaccine ensures, on the one hand, that the infection process necessary for the induction of an immune response takes place and, on the other hand, that the formation of additional antigen by a hybrid live vaccine does not disturb the infection process in order to finally achieve an effective immune response to the additional antigen and the pathogen cross-reacting therewith.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU ⁺	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE*	Germany	MC	Monaco	US	United States of America
DK	Denmark				

⁺ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

Two-phase system for the production and presentation of
foreign antigens in hybrid live vaccines

The method common in medicine of producing effective protection against infectious diseases in human beings and animals is based on the principle of active immunisation by using pathogen-specific antigens. There are, for example, prophylactic vaccinations against a number of diseases in human beings which are caused by bacteria or viruses. However, vaccinations against fungi and parasites are possible in principle too.

The basis for the protective effect of such vaccines is that important antigens, which in general originate or are derived from the pathogen, are brought into contact with the immune system of human beings or animals by infection or another suitable administration so that a specific immune response directed to the administered antigens is induced. The aim and object of this is to select the administered antigens in such a way and to present them to the immune system such that the induced immune response is directed against the pathogen and a subsequent infection is thus prevented. The induced immune response can be of either humoral (based on antibodies) or cellular nature or both.

The vaccine containing or forming antigens can be constructed or composed in a different way (see Bloom, Nature, 342:115-120, 1989). A simple method consists in using killed pathogens as the vaccine. Improvements are often achieved by only employing a few isolated components of the pathogen in the vaccine which represent important

antigens. Moreover, new vaccines often only contain a few well-defined (e.g. purified from the pathogen, or prepared by genetic engineering or otherwise) components which act as an antigen by suitable presentation. Furthermore, every combination of the cited possibilities is conceivable. The common factor of the vaccines is that they consist of inactivated antigen material.

In contrast to these inactivated vaccines, the further possibility of immunising with biologically intact pathogens (so-called live vaccines) and conveying effective protection has long been known. Vaccination with living viruses (Zanetti, Immunology Today, 8:18-25, 1987) and BCG bacteria (Lotte, Adv. Tuberc. Res. 32:107-193, 1984) fall under this category, for example, as well as oral immunisation with living Ty21a Salmonella (Germanier, J. Infect. Dis. 131:553-558, 1975). The principle of such live vaccines is based on the use of an attenuated (or immunologically related non-virulent for a certain species) pathogen strain which is able to cause infection and effective immunological protection against the actual pathogen but is no longer pathogenic per se. Experience in the application of live vaccines lies above all with viruses and bacteria; in principle, however, similar vaccines can also be developed on the basis of fungi and parasites. Live vaccines often have advantages over comparable inactivated vaccines because they e.g. convey better immunological protection and are safer and less expensive.

New developments have furthermore shown that it is possible to change live vaccines by genetic engineering so that they not only present their own antigens to the immune system but also additional antigens which are derived from a different pathogen species. With such hybrid live vaccines it is possible to achieve immunological protection not only against the pathogen from which the live vaccine is derived or with which it is related but also against pathogens

against which the immune response to the additional antigen is directed. Depending on the species on which the live vaccine is based, one or more additional antigens can be presented to the immune system and immunological protection can thus be conveyed. This is already realizable in practice with viral and bacterial live vaccines (see Dougan, J. Gen. Microbiol. 135:1397-1406, 1989). In contrast to bacterial or other cellular live vaccines, it is however natural for viral live vaccines (as well as for viruses in general) to be able to express their genetic information only after infection of a cell. In this case the formation of additional antigen by a viral live vaccine consequently requires the infection of cells of the individual to be protected. The presentation of additional antigens to the immune system can on the one hand take place via the infected cell per se or on the other hand via the viral live vaccine which carries additional antigen in its packaging.

A considerable problem with the construction and use of such hybrid live vaccines is however the circumstance that the production of additional antigens often changes the biological properties of the live vaccine and destabilizes the immunological effect so that the desired immunological protection is not achieved or only to a reduced extent. This can be the case in particular if the additional antigen is produced in large quantities as would often be required for the induction of a good immune response, and/or if the additional antigen is otherwise toxic for the live vaccine itself. In other words: The hybrid live vaccine behaves differently to the original live vaccine with respect to the course of an infection and thus with respect to its immunisation potential because it produces one or more additional antigens. This also means that, depending on the kind of additional antigens produced by the live vaccine, the infectious properties and the effectiveness of the immunisation of the live vaccine cannot be inferred in so

far as it is at all possible to achieve an effective immune response.

Current experiments to solve this problem in bacterial systems pursue the goal of controlling the formation of additional antigens in a live vaccine by external influences, i.e. to bring the genes which code for the formation of additional antigens under the control of an inducible promoter. The additional antigens of the live vaccine would consequently only be formed in dependence on their external influences or the environment. Such external influences can be e.g. a certain substance or a certain temperature (e.g. lac system: De Boer, Proc. Natl. Acad. Sci. USA, 80:21-25, 1983; P₁-system: Remaut, Gene, 15:81-93, 1981). It would be ideal if the external influences required for the formation of the antigens were only to be present where the live vaccine came into contact with the immune system but not in the course of the infection process so that the infection process necessary for the immune response is not disturbed. However, this is hardly realizable in practice not only because the infection process and the initiation of contact with the immune system are biologically linked but also because the conditions at the site of action of the live vaccine, i.e. in certain areas of the body of the person to be vaccinated, can be purposefully controlled with the available means neither with respect to location nor with respect to time.

It is therefore the object of the present invention to introduce a genetic element into the construction of hybrid live vaccines which, on the one hand, allows the production of sufficiently large quantities of additional antigen at the immunological site of action and, on the other hand, does not interfere with the course of infection by the hybrid live vaccine and thus the expected immunological protection. This object was achieved by making the formation of the additional antigens of the hybrid live vaccine

dependent on random genetic events which occur relatively frequently. This principle implies the existence of two subpopulations/phases which originate from the live vaccine, namely of the hybrid live vaccine itself (subpopulation/phase A) which does not produce any additional antigen and therefore reproduces without its properties changing in relation to the original strain and is capable of a normal course of infection and a normal immune response, and a subpopulation/phase B which may have lost these properties but is constantly newly regenerated from subpopulation A and releases large quantities of additional antigen at the site of action (see Fig. 1). Subpopulation A therefore has the task of guaranteeing a perfect course of infection while subpopulation B serves to build up an effective immune response to the additionally formed antigens.

Random events which lead to the formation of subpopulations are natural and can mostly be traced back to changes in the DNA, so-called (programmed) DNA reorganisations (Borst, Science, 235:658-667, 1987). In principle, all naturally-observed mechanisms of DNA reorganisation can be used for the task set, provided that they can be reproduced suitably frequently in the hybrid live vaccine. The frequency of the formation of subpopulation B is preferably 0,1% to 50% per cell and cell generation; in particular cases, the frequency can, however, be higher or lower. Particularly suitable for application in a hybrid live vaccine are simple mechanisms of DNA reorganisation which occur at specific sites, such as inversion (Craig, Cell, 41:649-650, 1985) or deletion by resolution of transposon cointegration (Grindley, Annual Rev. Biochem., 54:863-896, 1985) of a DNA segment. However, other site-specific DNA reorganisations or such DNA reorganisations which are based on slipped-strand-mispairing (Levinson, Mol. Biol. Evol. 4:203-221, 1987; Stern, Cell, 47:61-71, 1986) seem suitable for the cited object.

It must be the purpose of the cited spontaneously occurring DNA reorganisation in a live vaccine to lead directly or indirectly to the production of additional antigen, i.e. to the formation of subpopulation B which produces the antigen. This occurs very simply e.g. by positioning an expression signal (for example the promoter) of a gene by DNA reorganisation in front of the gene such that said gene changes from a non-expressed to an expressed state. All variants of this principle are possible; but they all have the goal of bringing about a change in the expression of a gene by DNA reorganisation (see Fig. 2 and Fig. 3). It usually makes sense to switch on genes by DNA reorganisation although the opposite is also possible.

The gene switched on by DNA reorganisation can, on the one hand (model I), be the gene coding for an additional antigen or (if the additional gene is not a protein but an enzymatic synthesis product, e.g. a carbohydrate) a gene required for the antigen synthesis, or, on the other hand (model II), a gene encoding a protein which controls the expression of the actual gene coding for the antigen. Model I is thus a system which by DNA reorganisation directly codes for the synthesis of the additional antigen or for an enzyme required for the synthesis while model II represents a system which allows the production of the additional antigen via a cascade system (see Fig. 2 and Fig. 3). The cascade system can be realized e.g. in that the gene directly controlled by DNA reorganisation codes for an RNA polymerase which is specific for the promoter preceeding the gene coding for the antigen, or a gene regulator which in another specific manner induces the expression of the gene coding for the antigen (e.g. T7 polymerase: Studier, Meth. Enzymol. 185:60-89, 1990; lac system: De Boer, Proc. Natl. Acad. Sci. USA, 80:21-25, 1983). In this case too, there are all the possibilities of variation which nature offers. Whilst model I is on the one hand less complicated, the application of model II has advantages because high levels of expression can be achieved

after one single DNA reorganisation due to the increasing effect of the cascade. Furthermore, with this model several genes which code for different additional antigens within one hybrid live vaccine can be switched on at the same time.

The realization of the described system is technically particularly simple in bacterial live vaccines. The genetic element capable of DNA reorganisation can be held in bacteria e.g. on a plasmid or introduced in the genome by means of a phage, a transposon or by homologous recombination. In the case of the cascade model II, the antigen-encoding genes, which have special sites for the binding of the gene products of the element capable of DNA reorganisation, can be introduced in a similar manner by using conventional techniques.

Depending on the principle of the underlying DNA reorganisation enzymes (referred to here as "control enzymes") are necessary which have to be provided by the cell so that DNA reorganisation can take place at all. In the case of an inversion according to the principle of the phage Mu an invertase is necessary, for example, besides cellular factors (Kahmann, Cell, 41:771-780, 1985); in the case of a deletion corresponding to the mechanism of the resolution of transposon cointegration the enzyme resolvase is necessary, for example, (Reed, Cell, 25:713-719, 1981); the formation of replicative circles corresponding to the replication of filamentous phages requires inter alia the gene 2 product of the phage (Meyer, Nature, 296:828-832, 1982). These enzymes as well as the DNA structure at which they attack (referred to here as "target sites"; e.g.: Mertens, EMBO J., 7:1219-1227, 1988), offer a suitable basis from which to regulate the frequency with which DNA reorganisation forms the additional antigen and thus to determine the ratio of populations A and B. Manipulation of the expression of the control enzymes or the target sites by genetic engineering makes it possible to adjust this ratio

exactly to the desired ratio of the populations. However, it is also conceivable to subject the control enzymes in turn to a superordinate regulatory control in order to change the ratio of populations A and B by external influences (e.g. in dependence on the temperature) (see Fig. 2). Here, too, there are possibilities of variation as desired and given in the state of molecular biology.

The conventional methods of molecular biology serve for the construction of genetic elements which undergo DNA reorganisation. Moreover, it is advantageous to firstly clone such genetic elements in cells which do not synthesise control enzymes in order to keep them stable for manipulation and construction purposes. After preparation such elements can be inserted into the genome of the live vaccine by the conventional methods of molecular biology or can be kept extrachromosomally as a plasmid. The same applies to the genes which code for the control enzymes as well as with respect to genes indirectly or directly coding for antigens in the case of model II.

The final hybrid live vaccine is administered in a suitable manner (e.g. by oral dosage or by injection) to the individual to be protected. The administered dose of the hybrid live vaccine usually corresponds to that for the corresponding non-hybrid live vaccine.

Examples

Example 1

Construction of an invertible DNA element for the production of CT-B antigen (*Vibrio cholerae* toxin B - subunit) in *Salmonella*.

The genetic organisation of the invertible DNA element described here is represented in Figure 4. The element is

contained on the plasmid pYZ17 and was constructed by using the following genes or other nucleotide sequences:

The gin gene is derived from the plasmid pLMugin-X16 (Mertens, EMBO J. 3:2415-2421, 1984) and was removed from there firstly as partially cleaved PvuI fragment which still contained the PvuI cleavage site contained in the gin gene itself as the only uncleaved PvuI cleavage site. This PvuI fragment was provided with EcoRI linkers at its ends and after cleavage with EcoRI and BamHI isolated as a BamHI/EcoRI fragment. This fragment was linked at the BamHI cleavage site with a synthetic BamHI/ClaI fragment (5'-GGATAAACCGATACAATTAAAGGCTCCTTTTGGAGCCTTTTTTTTGGAGATTTTCAACG TG-3') of the terminator of bacteriophage fd so that a combinant EcoRI/ClaI fragment was obtained.

The cI857-gene fragment was isolated from the plasmid pRK248 (Bernard, Gene 5:59-76, 1979) by partial cleavage with HindIII and subsequent ligation with an XhoI linker as an XhoI/Cla fragment.

The EcoRI/ClaI gin fragment was ligated to the cI857 gene fragment via the ClaI cleavage site and incorporated as an EcoRI/XhoI fragment into a derivative (pYZ13) of the plasmid pBT192 (Zahm, Mol. Gen. Genet., 194:188-194, 1984) which carries an additional (EcoRI/ClaI/XhoI/BglIII) polylinker region.

The P₁ promoter was isolated as an XhoII fragment from the plasmid pLC2833 (Remaut, Gene 22:103-113, 1983) and linked via the BclI cleavage site at both ends with two synthetic BclI/XhoI oligonucleotides (5'-GATCATTTACCGTTTCCTGTAAACCGAGGTTTGGATAAC-3') which correspond to the IR sequences (inverted repeats). The resulting fragment consisting of the sequence "IR-P₁-IR" was inserted into the singular XhoI cleavage of plasmid pfdA4 (Geider, Gene 33:341-349, 1985).

The rrnB T1 transcriptional terminator was obtained as a SalI/XhoI fragment with the nucleotide sequence XhoI 5'-

TCGAGGTAGCGAGCTTGAGGCATCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGC
CTTTCGTTTTATCTGTTGTTTGTCTGGTGAACGCTCTCCTGAGTAGGACAAATCCGCCGGGAGCGGA
TTTGAACGTTGCGAAGCAACGGCCCGGAGGGTGGCGGGCAGGACGCCCGCCTTAAACTGCCACAAG
CTCGGTACCGTTAACG-3' SalI.

The promoterless CT-B encoding ctxB gene fragment was isolated from plasmid pTK1 (Klauser, EMBO J. 8:1991-1999, 1990) after cleavage with ClaI and subsequent linkage with a BglII linker as a BglII/SalI fragment.

The plasmid pYZ17 was constructed from the above-mentioned components in the following manner:

The SalI/XhoI T1 terminator fragment was inserted into the singular XhoI cleavage of plasmid pYZ13 and tested for the orientation of the remaining intact XhoI cleavage site. Derivatives from pYZ13 which carried the remaining XhoI cleavage site distally to the ci857 gene of pYZ13 were called pYZ15. The XhoI IR-P₁-IR fragment was inserted into the remaining XhoI cleavage site of pYZ16 so that the P₁ promoter was orientated to the ci857 gene. This plasmid (pYZ16) was identified by an asymmetric EcoRI cleavage (Fig. 4). Finally the neo^r gene contained in pYZ16 was replaced by the ctxB fragment by cleavage with BglII/SalI and subsequent ligation to give pYZ17 (Fig. 4). Since pYZ17 possesses a further EcoRI cleavage site downstream from gin besides the EcoRI cleavage site within the invertible P₁ promoter fragment, the orientation of the promoter can be determined very easily by cleavage with EcoRI, and the inversion of the promoters can be followed up very easily. The fractionation of the EcoRI cleavage products in an agarose gel results in two bands of defined size of phase A of plasmid pYZ17 corresponding to about 4960 bp and 1840 bp or two bands of

defined size of phase B of the same plasmid corresponding to 4630 bp and 2170 bp.

The construction and analysis of the described plasmids were carried out according to the methods described in Sambrook (Molecular Cloning, 2nd. ed., 1989, Cold Spring Harbor Laboratory Press). For explanation of the function of the invertible elements on plasmid pYZ17 see legend to Fig. 4. Fig. 5 shows evidence of the formation of CT-B antigen by the invertible element of plasmid pYZ17 in *S.typhimurium* SL3235 in comparison with plasmid pTK1 (Klauser, EMBO J., 9:1991-1999, 1990).

Example 2

Oral immunisation of BALB/c mice against CT-B antigen using a two-phase *Salmonella typhimurium* live vaccine

Salmonella typhimurium SL3235 (Hoiseth, Nature 291:238-239, 1981) was transformed according to the $MgCl_2/CaCl_2$ method (Lederberg, J. Bacteriol., 119:1072-1074, 1974) in separate preparations by plasmids pYZ17 and pTK1. The transformants were frozen in LB medium containing 15% glycerin and kept at $-75^{\circ}C$. Before the immunisation experiment these strains were firstly incubated overnight on LB plates containing ampicillin (100 mg/ml) at $28^{\circ}C$. Single colonies were then inoculated in 10 ml liquid LB medium containing ampicillin (50 mg/ml) and cultivated overnight at $28^{\circ}C$. 5 ml of these overnight cultures were then added to 20 ml LB medium having a temperature of $28^{\circ}C$ and containing ampicillin (50 mg/ml) and incubated for a further 4 hours at $28^{\circ}C$. The cultivated bacteria were subsequently harvested by centrifugation, washed in 10 ml saline (0.8% NaCl) and finally suspended in 2 ml saline.

The mice used for immunisation (BALB/c) were given water but no food for 16 hours before the vaccination. All the mice

were each given an oral dose of 0.2 ml 50% saturated Na_2HCO_3 solution. The mice were then divided up into groups of 5 and 30 minutes later were each given 0.2 ml of the prepared bacteria suspension administered gastrally with a blunt vaccination cannula: *S.typhimurium* SL3235 (group 1), *S.typhimurium* SL3235/pTK1 (group 2) or *S.typhimurium* SL3235/pYZ17 (group 3). The oral immunisation took place at 3 intervals (day 0, 7 and 14) with the same dosage each time. On day 20, serum and intestinal fluid were collected (Manning, FEMS Microbiol. Lett., 28:317-321, 1985). Protease inhibitor was added to the removed intestinal fluid (Elson, J. Immunol. Meth., 67:101-108, 1984). The samples of the mice were pooled according to the groups and determined by means of class-specific goat-anti-mouse antibodies in the ELISA test with respect to their specific antibody titer (Elson, J. Immunol. Meth., 67:101-108, 1984). The results are shown in Table 1.

Figures and Tables

The present invention is illustrated by the following figures in combination with the description and the examples.

Fig. 1. Schematic representation of the spontaneous formation of two subpopulations/phases (A and B) of a cellular live vaccine.

The figure is an idealization of the exponential reproduction of one cell of the live vaccine (e.g. of a bacterium) which carries a genetic element according to the present invention which leads to the spontaneous formation of two subpopulations/phases A (open ellipses) and B (closed ellipses). While cells remain reproductive in phase A and therefore capable of infecting, spontaneously formed cells of phase B form large quantities of additional antigen which, on the one hand, leads to the induction of an

additional immune response but, on the other hand, may inhibit the further reproduction of phase B. In the presented case the frequency of the formation of phase B is about 20%.

Fig. 2. Example of a specific DNA deletion in accordance with model I of the invention taking into account the role of the control enzyme.

X represents the antigen-encoding gene which is separated in phase A from its promoter (P_X) by a transcription terminating segment (U) and is therefore not expressed while in phase B the promoter is positioned directly in front of the gene X so that said gene is expressed. The deletion of the DNA segment U occurs by site-specific recombination at the sites IRS ("internal resolution sites" of the transposon Tn3) by the enzyme resolvase (TnpR of the transposon Tn3; here: closed, downwards pointing triangle). For this it is important that the two IRS sites whose nucleotide sequence is defined, are orientated in the same direction and are preferably localised within some 100 to 1000 base pairs on the same DNA molecule. The frequency of the deletion event can be determined by a number of factors, for example by slight sequence changes of one or both IRS sites or by the quantity of resolvase present in the cell. The quantity of this enzyme present in turn depends on the efficiency of the expression of the resolvase-encoding gene R. Provided that this gene in combination with its promoter (P_R) possesses an operator (O_R) on which transcription regulators can bind, it is possible in principle to regulate the frequency of the DNA reorganisation (deletion of segment U) via the expression levels of the control-enzyme-encoding gene (R) by external influences, e.g. temperature.

Fig. 3 Example of a specific DNA inversion in accordance with model II of the invention.

The genes X and Y represent antigen-encoding genes which are contained e.g. on a plasmid of a hybrid bacterial live vaccine in any arrangement. Promoters (P_X and P_Y) proceed these genes and are specific for certain RNA polymerases (e.g. the polymerase of phage T7) which are not formed by the live vaccines/bacterial cells themselves. In phase A the genes X and Y cannot be expressed since the specific polymerase is lacking. However, the live vaccine/bacterial cell contains the gene (S) which codes for this polymerase. The gene S can now be activated e.g. by DNA inversion whereby the promoter P_S is positioned directly in front of the polymerase gene S by the inversion of a segment so that said gene is expressed. The inversion of the DNA segment containing the promoter is catalysed (e.g. in analogy to the G segment of the bacteriophage Mu) by an enzyme (gin/invertase) which attacks at well-defined target sites (IR/inverted repeats) which hold the opposite orientation on the DNA. The frequency with which the inversion of the fragment carrying the promoter occurs depends on several factors (inter alia the quantity of the invertase present in the cell and the structure of the IR sites at which it attacks) and can be individually adjusted or changed by manipulation by genetic engineering. In this example, the site-specific inversion of a DNA segment thus initiates a cascade which finally effects the activation of the antigen-encoding genes X and Y.

Fig. 4 Example of a genetic element according to the present invention for a bacterial live vaccine and the nature of its effect.

In the figure, the sketches A and B are the two phases of an invertible element, corresponding to how this can be present in the subpopulations A or B after introduction into a bacterial strain. The element shown essentially corresponds to model I (direct expression of the antigen gene) and possesses a superordinate regulatory control function which

is dependent on the temperature as an external influence. In phase A the promoter P_1 (PL) responsible for the expression of the antigen gene is directed in the direction of the *cI857* gene, which codes for a superordinate temperature sensitive repressor, and the *gin* gene, which codes for the control enzyme. The consequence of this is that a repressor which is able to function is formed at the permissive temperature of 28°C and reduces the transcription from the P_1 promoter (PL). At a higher temperature (e.g. 37°C) the transcription of the P_1 promoter (PL) is increased since the repressor is inactivated at least partially under such external influences. The temperature-dependent increase in the transcription also causes a corresponding increase in the expression of the following *gin* gene which as a control enzyme catalyses the inversion of the promoter at the target sites. Thus, the frequency of the inversion is also increased by a higher temperature and thus the transition of the invertible element in phase B. However, the inversion at a lowered temperature is not completely prevented since the *gin* gene is always expressed on a low level anyway and, moreover, because the host cell itself which is used as the live vaccine usually possesses an active gene similar to *gin*.

The inversion of the promoter causes less repressor and less control enzyme to be formed on the one hand and the antigen-encoding gene (CT-B) to be strongly expressed by means of the inverted promoter and due to the weaker formation of the *cI* repressor on the other hand.

In the above example, the invertible element is contained in the *Salmonella typhimurium* live vaccine (SL3235) on the plasmid pYZ17. Since this plasmid is present in several copies per bacterial cell, elements of both phase A and phase B can be present in a single bacterial cell. This results in additional interactions between the plasmids of phases A and B which cause a fractionation of the live

vaccine not only in two subpopulations but also in the intermediates in between. If this is not desired, this can be easily taken care of by integration of the invertible element into the chromosome of the live vaccine or by cloning the element on a single copy plasmid.

For further functional analysis of the invertible element contained in plasmid pYZ17 on the plasmid pYZ17 see also Fig. 5 and Tab. 1. In the drawing the abbreviations mean as follows: Eco, EcoRI restriction sites for the analysis of the phase state of the invertible element; gin (also gin in the text), the gene coding for the control enzyme (invertase); T, transcription terminators for the reduction of the gene expression; cI (more precisely referred to in the text as cI857), the gene coding for the temperature-sensitive regulator (repressor); IR, the target sites of the invertase (inverted repeats); PL (also referred to in the text as P₁), the invertible promoter which is regulatable by the cI857 repressor; CT-B, the gene (ctxB) coding for the antigen (V.cholerae toxin B-subunit).

Fig. 5. This figure shows an immunoblot (Western) analysis of the formation of CT-B antigen in hybrid S.typhimurium SL3235 cells. In the figure, 20 ng of purified CT-B antigen obtained from Sigma is shown as a reference in lane 1 and 2.5×10^7 cells corresponding to bacterial lysates in lanes 2 to 6; lane 2, S.typhimurium SL3235 cultured at 37°C; lane 3, S.typhimurium SL3235 (pTK1) cultured at 28°C; lane 4, S.typhimurium SL3235 (pTK1) cultured at 37°C; lane 5, S.typhimurium SL3235 (pYZ17) cultured at 28°C; lane 6, S.typhimurium SL3235 (pYZ17) cultured at 37°C. Position "a" refers to an unspecific cross reaction in the blot, position "b" to the precursor of the CT-B antigen and position "c" to the mature CT-B antigen. The samples are obtained and the immunoblot is performed according to Klauser (EMBO J., 9:1991-1999, 1990).

It is apparent that *S.typhimurium* SL3235 (pYZ17) produces very little CT-B antigen at 28°C in contrast to at 37°C. It is further evident that in contrast thereto the formation of CT-B antigen in the reference strain *S.typhimurium* SL3235 (pTK1) is independent of temperature and that in this strain in relation to *S.typhimurium* SL3235 (pYZ17), which was cultured at 37°C, less CT-B precursor protein is accumulated. The latter reflects the formation of little CT-B antigen in subpopulation A and much CT-B antigen in subpopulation B in *S.typhimurium* SL3235 (pYZ17) cultured at 37°C: The formation of much CT-B in only a few cells leads to a hold-up in the conversion from precursor into mature CT-B antigen.

Tab. 1 Humoral immune response after oral immunisation of BALB/c mice with hybrid *Salmonella typhimurium* SL3235 strains.

The results of the experiment described in Example 2 are represented. The antibody titers stated therein correspond to those dilution levels of the samples which only just give a positive result in the ELISA test.

Table I

	ELISA titer		
	Serum		Intestinal lavage
	IgG	IgA	IgG
SL3235	20	8	8
SL3235 (pTK1)	640	16	16
SL3235 (pYZ17)	10240	128	64

Patent Claims


1. Hybrid live vaccine, characterized in that it comprises two subpopulations (A and B), whereby population A is capable of infecting and acts immunogenically per se while subpopulation B, which is regenerated from subpopulation A, produces additional antigen and acts immunogenically with respect to said additional antigen.
2. Hybrid live vaccine according to claim 1, characterized in that subpopulation B occurs with frequency of 0.1% to 50% per cell and cell generation.
3. Hybrid live vaccine according to claim 1 or 2, characterized in that it comprises a recombinant DNA which produces subpopulations A and B.
4. Hybrid live vaccine according to claim 3, characterized in that the recombinant DNA is contained in a cellular live vaccine.
5. Hybrid live vaccine according to claim 3, characterized in that the recombinant DNA is contained in a viral live vaccine and is expressed after infection of a cell.
6. Hybrid live vaccine according to claim 4, characterized in that the recombinant DNA is contained in one or more copies in the cellular live vaccine.
7. Hybrid live vaccine according to claim 4, characterized in that the recombinant DNA is contained in the cellular live vaccine on a plasmid.

8. Hybrid live vaccine according to claim 4, characterized in that the recombinant DNA is contained in the chromosome of the cellular live vaccine.
9. Hybrid live vaccine according to claim 4, characterized in that the cellular live vaccine is a bacterium or an eukaryotic cell (e.g. a fungus cell).
10. Hybrid live vaccine according to claim 9, characterized in that the bacterium or the eukaryotic cell is an attenuated pathogen.
11. Process for the preparation of a hybrid live vaccine, characterized in that the live vaccine is divided into two subpopulations (A and B), whereby population A is capable of infecting and acts immunogenically per se while subpopulation B, which is regenerated from subpopulation A, produces additional antigen and acts immunogenically with respect to said additional antigen.
12. Process according to claim 11, characterized in that the division of the live vaccine into two subpopulations occurs by spontaneous DNA reorganisation in the DNA of the live vaccine.
13. Process according to claim 12, characterized in that the DNA reorganisation is based on a specific DNA inversion process.
14. Process according to claim 12, characterized in that the DNA reorganisation is based on a specific DNA deletion process.
15. Process according to claim 12, characterized in that the DNA reorganisation is based on a specific DNA replication process.

16. Process according to claim 12, characterized in that the DNA reorganisation is based on slipped-strand-mispairing.
17. Process according to claim 12, characterized in that the spontaneous DNA reorganisation is catalysed by a control enzyme.
18. Process according to claim 17, characterized in that the frequency of the spontaneous DNA reorganisation is controlled superordinately by regulation of the control enzyme.
19. Process according to claim 12, characterized in that the subpopulation B is produced with a frequency of between 0.1% and 50% per cell and cell generation.
20. Process according to any one of claims 11 to 19, characterized in that the DNA reorganisation leads directly to the formation of additional antigen in subpopulation B.
21. Process according to any one of claims 11 to 19, characterized in that the DNA reorganisation initiates a cascade reaction and leads indirectly to the formation of additional antigen in subpopulation B.
22. Process according to claim 21, characterized in that the cascade is initiated by formation of a specific polymerase, whereby the latter directly or indirectly causes the expression of the gene(s) coding for the antigen.
23. Process according to claim 21, characterized in that the cascade is initiated by formation of a specific gene regulator which directly or indirectly causes the expression of the gene(s) coding for the antigen.

24. Recombinant DNA, characterized in that it produces a live vaccine according to claim 1.
25. Recombinant DNA according to claim 24, characterized in that it is contained in a cellular live vaccine.
26. Recombinant DNA according to claim 24, characterized in that it is contained in a viral live vaccine and expressed after infection of a cell.
27. Recombinant DNA according to claim 25, characterized in that it is contained in one or more copies in the cellular live vaccine.
28. Recombinant DNA according to claim 25, characterized in that it is contained in the cellular live vaccine on a plasmid.
29. Recombinant DNA according to claim 25, characterized in that it is contained in the chromosome of the cellular live vaccine.
30. Process for the immunisation of a mammal with a hybrid live vaccine, characterized in that a live vaccine according to any one of claims 1-10 is employed.

Fig. 1






Fig. 2





Fig. 4









Fig. 5

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 91/02478

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) * According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁵ : A 61 K 39/00, C 12 N 15/00, A 61 K 39/12											
II. FIELDS SEARCHED <div style="text-align: right; font-size: small;">Minimum Documentation Searched †</div> <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none;">Classification System </td> <td style="width: 50%; border: none;">Classification Symbols</td> </tr> <tr> <td style="border: none; vertical-align: top;">IPC⁵</td> <td style="border: none; vertical-align: top;">A 61 K, C 12 N</td> </tr> </table> <div style="text-align: center; font-size: x-small; margin-top: 10px;"> Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched * </div>			Classification System	Classification Symbols	IPC ⁵	A 61 K, C 12 N					
Classification System	Classification Symbols										
IPC ⁵	A 61 K, C 12 N										
III. DOCUMENTS CONSIDERED TO BE RELEVANT* <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%; font-size: x-small;">Category *</th> <th style="width: 70%; font-size: x-small;">Citation of Document, †† with indication, where appropriate, of the relevant passages ‡‡</th> <th style="width: 20%; font-size: x-small;">Relevant to Claim No. ††</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top;">A</td> <td style="vertical-align: top;"> EP, A2, 0 263 591 (DIRECTOR GENERAL OF NATIONAL INSTITUTE OF HEALTH) 13 April 1988 (13.04.88), see totality. </td> <td style="text-align: center; vertical-align: top;"> 1, 5, 11, 24, 26 </td> </tr> <tr> <td style="text-align: center; vertical-align: top;">A</td> <td style="vertical-align: top;"> EP, A2, 0 024 956 (RESEARCH CORPORATION) 11 March 1981 (11.03.81), see claims. </td> <td style="text-align: center; vertical-align: top;"> 1 </td> </tr> </tbody> </table>			Category *	Citation of Document, †† with indication, where appropriate, of the relevant passages ‡‡	Relevant to Claim No. ††	A	EP, A2, 0 263 591 (DIRECTOR GENERAL OF NATIONAL INSTITUTE OF HEALTH) 13 April 1988 (13.04.88), see totality.	1, 5, 11, 24, 26	A	EP, A2, 0 024 956 (RESEARCH CORPORATION) 11 March 1981 (11.03.81), see claims.	1
Category *	Citation of Document, †† with indication, where appropriate, of the relevant passages ‡‡	Relevant to Claim No. ††									
A	EP, A2, 0 263 591 (DIRECTOR GENERAL OF NATIONAL INSTITUTE OF HEALTH) 13 April 1988 (13.04.88), see totality.	1, 5, 11, 24, 26									
A	EP, A2, 0 024 956 (RESEARCH CORPORATION) 11 March 1981 (11.03.81), see claims.	1									
<div style="display: flex; justify-content: space-between; font-size: x-small;"> <div style="width: 45%;"> <p>* Special categories of cited documents: ††</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 50%;"> <p>† later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Z" document member of the same patent family</p> </div> </div>											
IV. CERTIFICATION <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;"> Date of the Actual Completion of the International Search <div style="text-align: center;">25 March 1992</div> </td> <td style="width: 50%; border: none; vertical-align: top;"> Date of Mailing of this International Search Report <div style="text-align: center;">14. 04. 92</div> </td> </tr> <tr> <td style="width: 50%; border: none; vertical-align: top;"> International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div> </td> <td style="width: 50%; border: none; vertical-align: top;"> Signature of Authorized Officer <div style="text-align: center;">  Natalie Weinberg </div> </td> </tr> </table>			Date of the Actual Completion of the International Search <div style="text-align: center;">25 March 1992</div>	Date of Mailing of this International Search Report <div style="text-align: center;">14. 04. 92</div>	International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;">  Natalie Weinberg </div>					
Date of the Actual Completion of the International Search <div style="text-align: center;">25 March 1992</div>	Date of Mailing of this International Search Report <div style="text-align: center;">14. 04. 92</div>										
International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;">  Natalie Weinberg </div>										

ANHANG

ANNEX

ANNEXE

zum internationalen Recherchen-
bericht über die internationale
Patentanmeldung Nr.

to the International Search
Report to the International Patent
Application No.

rapport de recherche inter-
national relatif à la demande de brevet
international n°

PCT/EP 91/02478 SAE 54548

In diesem Anhang sind die Mitglieder
der Patentfamilien der im obenge-
nannten internationalen Recherchenbericht
angeführten Patentdokumente angegeben.
Diese Angaben dienen nur zur Unter-
richtung und erfolgen ohne Gewähr.

This Annex lists the patent family
members relating to the patent documents
cited in the above-mentioned inter-
national search report. The Office is
in no way liable for these particulars
which are given merely for the purpose
of information.

La présente annexe indique les
membres de la famille de brevets
relatifs aux documents de brevets cités
dans le rapport de recherche inter-
national visée ci-dessus. Les renseigne-
ments fournis sont donnés à titre indica-
tif et n'engagent pas la responsabilité
de l'Office.

Im Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche		Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
EP A2	263591	13-04-88	CN A 87106793	20-07-88
			EP A3 263591	24-05-89
			JP A2 63063381	19-03-88
EP A2	24956	11-03-81	AU A1 58556/80	27-11-80
			AU B2 536370	03-05-84
			DE C0 30711115	31-10-85
			DK A 260781	21-01-81
			DK E 161492	15-07-91
			DK C 161492	13-01-92
			EP A3 24956	02-12-81
			EP B1 24956	25-09-85
			IE B 50598	28-05-86
			JP T2 56500612	07-05-81
			NZ A 193815	21-12-82
			US A 4337314	29-06-82
			WO A1 8002504	27-11-80
			US A 4681762	21-07-87